Biomarkers Predicting Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Predictive Biomarkers for Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial
Nat Commun 2022 Apr 06;13(1)1878, MS van der Heijden, T Powles, D Petrylak, R de Wit, A Necchi, CN Sternberg, N Matsubara, H Nishiyama, D Castellano, SA Hussain, A Bamias, G Gakis, JL Lee, ST Tagawa, U Vaishampayan, JB Aragon-Ching, BJ Eigl, RR Hozak, ER Rasmussen, MS Xia, R Rhodes, S Wijayawardana, KM Bell-McGuinn, A Aggarwal, A DrakakiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.